Makers of brand-name biologic drugs appear to be sowing public doubt about the safety and efficacy of biosimilars, according to FDA Commissioner Scott Gottlieb, as well as physicians and some drugmakers.
Gottlieb warns biologics makers may be sowing skepticism about biosimilars
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.